Evan Greebel Conspired with Martin Shkreli to Steal Millions
of Dollars from a Biopharmaceutical Company and Conceal the Scheme
Earlier today, in federal court in Brooklyn, Evan Greebel, a
former partner at the New York office of Katten Muchin Rosenman LLP who served
as outside counsel to Retrophin, Inc., a biopharmaceutical company, was
sentenced by Judge Kiyo A. Matsumoto to 18 months’ imprisonment for conspiracy
to commit wire fraud and conspiracy to commit securities fraud, to be followed
by three years’ supervised release. The
Court also ordered Greebel to pay $116,462.03 in forfeiture and $10,447,979 in
restitution. Greebel was convicted by a
federal jury in December 2017, following an 11-week trial, for his role in two
interrelated fraud schemes with Retrophin CEO Martin Shkreli and others, in
which Greebel, Shkreli and others stole millions of dollars in cash and stock
from Retrophin and manipulated the price and trading volume of Retrophin stock.
Richard P. Donoghue, United States Attorney for the Eastern
District of New York, and William F. Sweeney, Jr., Assistant
Director-in-Charge, Federal Bureau of Investigation, New York Field Office
(FBI), announced the sentence.
“Today’s sentence reinforces our message that attorneys who
facilitate crimes will be held accountable for their actions,” stated United
States Attorney Donoghue. “Evan Greebel
leveraged his legal training and the trust placed in him by Retrophin’s Board
of Directors to commit serious crimes, including the theft of millions of dollars
in cash and stock from the very company he was hired to represent. In doing so, Greebel broke the law and
violated the ethical duties he owed to his client.” Mr. Donoghue expressed his thanks to the
United States Securities and Exchange Commission (SEC), New York Regional
Office, and the Financial Industry Regulatory Authority, Inc., Criminal
Prosecution Assistance Group (FINRA CPAG), for their significant cooperation
and assistance in this case.
“As an attorney well-versed in the law, Greebel was expected
to abide by it – not violate it,” stated FBI Assistant Director-in-Charge
Sweeney. “Instead he used his
professional expertise to prepare illegitimate agreements, allowing him and
others to carry out their illegal activity.
His sentencing today serves as a reminder to others that there are
consequences for this type of behavior.”
Between 2011 and 2014, Greebel conspired with Shkreli and
others to misappropriate Retrophin’s assets in order to pay off defrauded
investors in Shkreli’s hedge funds, MSMB Capital Management LP (MSMB Capital)
and MSMB Healthcare Management LP (MSMB Healthcare). Specifically, Greebel negotiated and prepared
so-called settlement agreements with various of the defrauded investors, causing
Retrophin to reimburse them more than $2 million in cash and stock. Greebel also arranged for other defrauded
investors to enter into sham consulting agreements with Retrophin as a means to
settle liabilities owed by Shkreli and the hedge funds.
In addition, between 2012 and 2014, Greebel and Shkreli
schemed to defraud investors in Retrophin by attempting to control illegally
the price and trading volume of Retrophin’s stock. As part of the scheme, they concealed
Shkreli’s beneficial ownership and control of most of Retrophin’s free-trading
shares, recruited associates of Shkreli to be nominee holders of those shares
and prevented the nominees from selling the shares. Some of the shares were used to settle
liabilities owed by the MSMB hedge funds and Shkreli.
The government’s case is being handled by the Office’s
Business and Securities Fraud Section.
Assistant United States Attorneys Alixandra Smith, David Pitluck and
David K. Kessler are in charge of the prosecution.
The Defendant:
EVAN GREEBEL
Age: 45
Scarsdale, New York
E.D.N.Y. Docket No. 15-CR-637 (KAM)
No comments:
Post a Comment